article

In biotech investing, diligence is usually strong on biological risk: target validation, mechanistic plausibility, safety signals. But there’s another risk that is more predictable, more auditable, and still routinely under-examined: Design risk — when a trial’s implicit assumptions (about population, endpoints, adherence, measurement, site behavior, missingness, or operational drift) fail under real-world conditions. Late-stage programs…

Article Most teams explain late-stage failure with familiar labels: “Biology is hard.” “The animal model wasn’t predictive.” “The trial was underpowered.” “Regulators are strict.” “The execution team wasn’t strong.” Sometimes those are true. But the pattern underneath many failures is different — and more actionable: A result can be scientifically correct… and still fail because…

The Hidden Cost of Low-Information Data | Method2Model Article Why most clinical studies don’t suffer from “too little data”, they suffer from the wrong data at the wrong time. And how Method2Model fixes it. Clinical research has a quiet cost problem that rarely shows up in budgets, until it’s too late. Often, the highest hidden…

Model-first ALD Bridging: Decision-grade specification before wet-lab spend Article Rare disease Dual-platform mRNA delivery Decision-grade modeling Model-first ALD Bridging: decision-grade specification before wet-lab spend In rare, rapidly progressive diseases like X-linked adrenoleukodystrophy (ALD)—especially cerebral ALD (cALD)—the scientific question is rarely the only bottleneck. The real bottleneck is time under uncertainty. In rare, rapidly progressive diseases…

Dual-platform mRNA programs multiply uncertainty—and teams often pay for that uncertainty with months of experiments, expensive animal cohorts, and late-stage surprises. This case report shows how Method2Model prevents that burn by making assumptions auditable, converting them into a code-ready specification, and tightening decision gates—so study designs stay interpretable, endpoints stay defensible, and irreversible spend is minimized while the therapeutic window is still open.

Targeted delivery systems for chemotherapy and immunotherapy aim to flip the traditional risk–benefit balance of cancer treatment: instead of flooding the whole body with toxic agents, they concentrate drug exposure where it matters most—the tumour. This article reviews the main technological families behind that shift, from liposomes, polymeric nanoparticles and antibody–drug conjugates to oncolytic viruses, exosomes and stimuli-responsive carriers. It contrasts platforms that are already in routine clinical use with those still in preclinical or early-trial stages, and evaluates how much each has actually improved survival, toxicity profiles and quality of life.

A time-limited “bridge” therapy with ABCD1 mRNA could help stabilize boys with cerebral ALD while they wait for definitive treatment with HSCT or gene therapy. By transiently restoring ALDP function, lowering toxic VLCFAs, and modestly slowing neuroinflammation, systemic and CNS-targeted mRNA dosing might “buy time” in real-world settings where logistics and access cause dangerous delays. This perspective outlines the biological rationale, design considerations, and a proposed peripheral-first → early-CNS framework for testing mRNA as a clinically realistic bridge rather than a competitor to curative options.

Computational modeling and coding are rapidly becoming central to modern biomedicine, from in silico simulations and AI-assisted drug discovery to patient-specific digital twins and deep-learning diagnostics. Yet despite these advances, modeling and data-driven methods are still underused in mainstream clinical research, held back by training gaps, poor standardization, and a disconnect between clinicians and computational scientists. Bridging this gap—by integrating modeling, simulation, and computational literacy into everyday biomedical practice—is essential for moving from descriptive to predictive medicine and building more precise, efficient, and ethical healthcare systems.

Animal models have underpinned biomedicine for decades, but up to 90% of preclinical findings still fail to translate in humans—wasting resources, exposing patients to risk, and creating ethical pressure to find better approaches. New Approach Methodologies (NAMs)—like organs-on-chips, advanced human cell systems, and in vitro assays—bring biology closer to the human reality, but remain mostly local in scale. By integrating NAMs with mechanistic, multi-scale computational modeling (PBPK, QSP, and systems models), we can bridge this gap, replace a substantial portion of animal use, and build a more predictive, human-centered, and regulatory-ready framework for preclinical development.

Computational modeling is reshaping how we discover and develop medicines by moving much of the exploration from patients into transparent, testable simulations. From virtual screening and PK/PD to QSP and in silico clinical trials, model-informed strategies help teams probe dose, variability, and trial design before large studies begin—reducing late-stage failures, protecting patients, and focusing resources on drugs that are more likely to work